Monitoring immunomodulation strategies in type 1 diabetes

Krishnamurthy, Balachander; Lacorcia, Matthew; Kay, Thomas W. H.; Thomas, Helen; Mannering, Stuart I.

doi:10.3389/fimmu.2023.1206874

Cited by 3 publications

(2 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The name in superscripts indicates the name of the peptide. The numbers in superscripts indicate the type of activity/peptide: 1 -opioid antagonist, 2 -smooth muscle-contracting peptide, 3 -ACEi-angiotensin-1-converting enzyme inhibitor, 4 -DPPIVi-dipeptidyl peptidase IV inhibitor, 5 -DPPIIIi-dipeptidyl peptidase III inhibitor, 6 -ACTH (adrenocorticotropic hormone) receptor antagonist, 7 -angiogenesis-stimulating peptide, 8 -anti-inflammatory peptide, 9 -anticarcinogenic peptide, 10 -antibacterial peptide, 11 -cytotoxic peptide, 12 -antifungal peptide, 13 -antioxidative peptide, 14 -AChEi-acetylcholinesterse inhibitor, 15 -BChEi-butyrylcholinesterase inhibitor, 16 -opioid agonist, 17 -peptide-regulating phosphoinositol metabolism, 18 -antiviral peptide. ImmDpimmunomodulating peptide, ImmSp-immunostimulating peptide, CN-casein, fr-fragment.…”

Section: Immunomodulatingmentioning

confidence: 99%

“…The human immune system plays a key role in the identification and removal of not only various potentially adverse substances (pathogens) but also aging and cancer cells [ 1 , 2 , 3 ]. It also mediates the control of inflammatory conditions [ 4 , 5 ], whereas its dysfunctions initiate the development of autoimmune diseases [ 3 , 6 ], including multiple sclerosis (MS) [ 3 , 7 ], rheumatoid arthritis (RS), systemic lupus erythematosus (SLE) [ 3 , 8 ], and type 1 diabetes mellitus (T1D) [ 3 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plant-Derived Proteins and Peptides as Potential Immunomodulators

Szerszunowicz,

Kozicki

2023

Molecules

View full text Add to dashboard Cite

The immune response of humans may be modulated by certain biopeptides. The present study aimed to determine the immunomodulatory potential of plant-derived food proteins and hydrolysates obtained from these proteins via monocatalytic in silico hydrolysis (using ficin, stem bromelainm or pepsin (pH > 2)). The scope of this study included determinations of the profiles of select bioactivities of proteins before and after hydrolysis and computations of the frequency of occurrence of selected bioactive fragments in proteins (parameter A), frequency/relative frequency of the release of biopeptides (parameters AE, W) and the theoretical degree of hydrolysis (DHt), by means of the resources and programs available in the BIOPEP-UWM database. The immunomodulating (ImmD)/immunostimulating (ImmS) peptides deposited in the database were characterized as well (ProtParam tool). Among the analyzed proteins of cereals and legumes, the best precursors of ImmD immunopeptides (YG, YGG, GLF, TPRK) turned out to be rice and garden pea proteins, whereas the best precursors of ImmS peptides appeared to be buckwheat (GVM, GFL, EAE) and broad bean (LLY, EAE) proteins. The highest number of YG sequences was released by stem bromelain upon the simulated hydrolysis of rice proteins (AE = 0.0010–0.0820, W = 0.1994–1.0000, DHt = 45–82%). However, antibacterial peptides (IAK) were released by ficin only from rice, oat, and garden pea proteins (DHt = 41–46%). Biopeptides (YG, IAK) identified in protein hydrolysates are potential immunomodulators, nutraceuticals, and components of functional food that may modulate the activity of the human immune system. Stem bromelain and ficin are also active components that are primed to release peptide immunomodulators from plant-derived food proteins.

show abstract

Section: Immunomodulatingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plant-Derived Proteins and Peptides as Potential Immunomodulators

Szerszunowicz,

Kozicki

2023

Molecules

View full text Add to dashboard Cite

show abstract

TRAJ23 Gene Targeting as a Therapeutic Strategy for Type 1 Diabetes: Implications from NOD Mouse Model Studies

Lai,

Luo,

Luo

et al. 2024

Preprint

View full text Add to dashboard Cite

Type 1 Diabetes (T1D) is an autoimmune disease characterized by the attack and destruction of Pancreatic islet beta cells by T cells. Understanding the role of T-cell receptor (TCR) in the development of T1D is of paramount importance. This study employs single-cell RNA sequencing (scRNA-seq) to delve into the mechanistic actions and potential therapeutic applications of autoreactive stem cell-like CD8 TCR in T1D. By retrieving T-cell data from non-obese diabetic (NOD) mice via the GEO database, it was revealed that CD8+ T cells are the predominant T-cell subset in the pancreatic tissue of T1D mice, along with the identification of T-cell marker genes closely associated with T1D. Moreover, the gene TRAJ23 exhibits a preference for T1D, and its knockout alleviates T1D symptoms and adverse reactions in NOD mice. Additionally, engineered TCR-T cells demonstrate significant cytotoxicity towards β cells in T1D.

show abstract

PPARs at the crossroads of T cell differentiation and type 1 diabetes

Riaz,

Wei,

Pan

2023

Front. Immunol.

View full text Add to dashboard Cite

T-cell-mediated autoimmune type 1 diabetes (T1D) is characterized by the immune-mediated destruction of pancreatic beta cells (β-cells). The increasing prevalence of T1D poses significant challenges to the healthcare system, particularly in countries with struggling economies. This review paper highlights the multifaceted roles of Peroxisome Proliferator-Activated Receptors (PPARs) in the context of T1D, shedding light on their potential as regulators of immune responses and β-cell biology. Recent research has elucidated the intricate interplay between CD4+ T cell subsets, such as Tregs and Th17, in developing autoimmune diseases like T1D. Th17 cells drive inflammation, while Tregs exert immunosuppressive functions, highlighting the delicate balance crucial for immune homeostasis. Immunotherapy has shown promise in reinstating self-tolerance and restricting the destruction of autoimmune responses, but further investigations are required to refine these therapeutic strategies. Intriguingly, PPARs, initially recognized for their role in lipid metabolism, have emerged as potent modulators of inflammation in autoimmune diseases, particularly in T1D. Although evidence suggests that PPARs affect the β-cell function, their influence on T-cell responses and their potential impact on T1D remains largely unexplored. It was noted that PPARα is involved in restricting the transcription of IL17A and enhancing the expression of Foxp3 by minimizing its proteasomal degradation. Thus, antagonizing PPARs may exert beneficial effects in regulating the differentiation of CD4+ T cells and preventing T1D. Therefore, this review advocates for comprehensive investigations to delineate the precise roles of PPARs in T1D pathogenesis, offering innovative therapeutic avenues that target both the immune system and pancreatic function. This review paper seeks to bridge the knowledge gap between PPARs, immune responses, and T1D, providing insights that may revolutionize the treatment landscape for this autoimmune disorder. Moreover, further studies involving PPAR agonists in non-obese diabetic (NOD) mice hold promise for developing novel T1D therapies.

show abstract

Monitoring immunomodulation strategies in type 1 diabetes

Cited by 3 publications

References 111 publications

Plant-Derived Proteins and Peptides as Potential Immunomodulators

Plant-Derived Proteins and Peptides as Potential Immunomodulators

TRAJ23 Gene Targeting as a Therapeutic Strategy for Type 1 Diabetes: Implications from NOD Mouse Model Studies

PPARs at the crossroads of T cell differentiation and type 1 diabetes

Contact Info

Product

Resources

About